MX365096B - Uso de paricalcitol en el tratamiento de la anemia inflamatoria. - Google Patents

Uso de paricalcitol en el tratamiento de la anemia inflamatoria.

Info

Publication number
MX365096B
MX365096B MX2016010104A MX2016010104A MX365096B MX 365096 B MX365096 B MX 365096B MX 2016010104 A MX2016010104 A MX 2016010104A MX 2016010104 A MX2016010104 A MX 2016010104A MX 365096 B MX365096 B MX 365096B
Authority
MX
Mexico
Prior art keywords
paricalcitol
treatment
erythropoeisis
stimulating agents
inflammatory anaemia
Prior art date
Application number
MX2016010104A
Other languages
English (en)
Other versions
MX2016010104A (es
Inventor
Giovanni Uriol Rivera Miguel
Original Assignee
Giovanni Uriol Rivera Miguel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giovanni Uriol Rivera Miguel filed Critical Giovanni Uriol Rivera Miguel
Publication of MX2016010104A publication Critical patent/MX2016010104A/es
Publication of MX365096B publication Critical patent/MX365096B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a el uso de paricalcitol, análogo sintético de la vitamina D, en el tratamiento de la anemia inflamatoria, preferentemente en combinación con agentes estimuladores de la eritropoyesis. El uso del paricalcitol para el tratamiento de dicha patología está asociado a un menor requerimiento de agentes estimuladores de la eritropoyesis, a una mejor utilización del hierro y a un incremento en los niveles de eritropoyetina plasmática, por parte de dichos pacientes. La presente invención describe además composiciones farmacéuticas que comprenden paricalcitol en combinación con agentes estimuladores de la eritropoyesis y excipientes farmacéuticamente aceptables, así como el uso de las mismas como medicamentos para el tratamiento de la anemia inflamatoria.
MX2016010104A 2014-02-11 2015-01-16 Uso de paricalcitol en el tratamiento de la anemia inflamatoria. MX365096B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201430177A ES2472040B1 (es) 2014-02-11 2014-02-11 Uso de paricalcitol en el tratamiento de la anemia inflamatoria
PCT/EP2015/050817 WO2015121022A1 (en) 2014-02-11 2015-01-16 Use of paricalcitol in the treatment of inflammatory anaemia

Publications (2)

Publication Number Publication Date
MX2016010104A MX2016010104A (es) 2017-01-06
MX365096B true MX365096B (es) 2019-05-22

Family

ID=51205045

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010104A MX365096B (es) 2014-02-11 2015-01-16 Uso de paricalcitol en el tratamiento de la anemia inflamatoria.

Country Status (16)

Country Link
US (1) US11464791B2 (es)
EP (1) EP3104872B1 (es)
JP (1) JP2017512753A (es)
KR (1) KR20160113664A (es)
CN (1) CN106061498B (es)
AR (1) AR099330A1 (es)
AU (1) AU2015217956B2 (es)
CA (1) CA2938057A1 (es)
DK (1) DK3104872T3 (es)
ES (2) ES2472040B1 (es)
IL (1) IL247207B (es)
MX (1) MX365096B (es)
PT (1) PT3104872T (es)
RU (1) RU2016131412A (es)
UY (1) UY35989A (es)
WO (1) WO2015121022A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022030665A1 (ko) * 2020-08-05 2022-02-10 경상대학교병원 조영제-유발 신독성 예방 또는 치료용 약학 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062620A2 (en) * 2003-01-13 2004-07-29 Cedars-Sinai Medical Center Paricalcitol as a chemotherapeutic agent
EP1737888A2 (en) * 2004-04-23 2007-01-03 Cambridge Antibody Technology LTD Erythropoietin protein variants
CA2674368A1 (en) * 2007-01-10 2008-07-17 Edison Pharmaceuticals, Inc. Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
CN102772364B (zh) * 2011-05-13 2015-12-02 重庆华邦制药有限公司 帕立骨化醇的脂肪乳及其制剂和制备方法

Also Published As

Publication number Publication date
IL247207B (en) 2020-02-27
DK3104872T3 (da) 2019-06-17
PT3104872T (pt) 2019-06-11
ES2472040R1 (es) 2014-09-18
CN106061498A (zh) 2016-10-26
CA2938057A1 (en) 2015-08-20
EP3104872B1 (en) 2019-03-13
IL247207A0 (en) 2016-09-29
CN106061498B (zh) 2019-12-06
US20160367571A1 (en) 2016-12-22
RU2016131412A (ru) 2018-03-15
MX2016010104A (es) 2017-01-06
ES2472040B1 (es) 2015-07-01
WO2015121022A1 (en) 2015-08-20
AU2015217956B2 (en) 2019-04-04
UY35989A (es) 2015-03-27
ES2728158T3 (es) 2019-10-22
US11464791B2 (en) 2022-10-11
ES2472040A2 (es) 2014-06-27
AR099330A1 (es) 2016-07-13
AU2015217956A1 (en) 2016-08-25
EP3104872A1 (en) 2016-12-21
KR20160113664A (ko) 2016-09-30
JP2017512753A (ja) 2017-05-25

Similar Documents

Publication Publication Date Title
NZ734233A (en) Pharmaceutical compositions comprising meloxicam
PH12021551189A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
IN2013MU01696A (es)
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
IN2014MU00303A (es)
IN2013MU00711A (es)
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2018005358A (es) Comprimido de dosis alta que contiene mesalazina optimizado.
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2018015363A (es) Metodos y composiciones para el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria.
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
MX365096B (es) Uso de paricalcitol en el tratamiento de la anemia inflamatoria.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
MX2017014301A (es) Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar.
MX2019008847A (es) Profarmacos de cisteamina.
NZ739679A (en) Cholecalciferol sulfate salts and their use for the treatment of vitamin d deficiency
MX2017008931A (es) Formulaciones farmaceuticas de xantina o derivados de xantina.
IN2014MU00077A (es)
IN2014CH00035A (es)
IN2014CH01195A (es)
MY187299A (en) An extract of tinospora crispa and use as an antihypercholesterolemic agent
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.

Legal Events

Date Code Title Description
FG Grant or registration